Bristol-Myers Squibb Co (BMY)
44.03
-0.08
(-0.18%)
USD |
NYSE |
May 17, 16:00
44.00
-0.03
(-0.07%)
After-Hours: 20:00
Bristol-Myers Squibb Enterprise Value: 135.32B for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
Date | Value |
---|---|
May 17, 2024 | 135.32B |
May 16, 2024 | 135.48B |
May 15, 2024 | 136.37B |
May 14, 2024 | 136.70B |
May 13, 2024 | 137.41B |
May 10, 2024 | 137.16B |
May 09, 2024 | 136.76B |
May 08, 2024 | 134.59B |
May 07, 2024 | 135.34B |
May 06, 2024 | 135.05B |
May 03, 2024 | 135.24B |
May 02, 2024 | 134.65B |
May 01, 2024 | 135.68B |
April 30, 2024 | 135.14B |
April 29, 2024 | 136.55B |
April 26, 2024 | 136.98B |
April 25, 2024 | 136.68B |
April 24, 2024 | 145.11B |
April 23, 2024 | 145.37B |
April 22, 2024 | 145.68B |
April 19, 2024 | 145.25B |
April 18, 2024 | 143.97B |
April 17, 2024 | 143.04B |
April 16, 2024 | 143.89B |
April 15, 2024 | 144.39B |
Date | Value |
---|---|
April 12, 2024 | 143.93B |
April 11, 2024 | 145.63B |
April 10, 2024 | 148.00B |
April 09, 2024 | 150.66B |
April 08, 2024 | 149.64B |
April 05, 2024 | 150.09B |
April 04, 2024 | 150.25B |
April 03, 2024 | 151.83B |
April 02, 2024 | 152.97B |
April 01, 2024 | 153.48B |
March 31, 2024 | 155.99B |
March 28, 2024 | 137.46B |
March 27, 2024 | 135.47B |
March 26, 2024 | 134.05B |
March 25, 2024 | 133.45B |
March 22, 2024 | 132.80B |
March 21, 2024 | 132.11B |
March 20, 2024 | 132.70B |
March 19, 2024 | 132.53B |
March 18, 2024 | 132.11B |
March 15, 2024 | 133.63B |
March 14, 2024 | 133.93B |
March 13, 2024 | 134.02B |
March 12, 2024 | 137.55B |
March 11, 2024 | 137.47B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
65.68B
Minimum
Jul 22 2019
202.63B
Maximum
Dec 02 2022
156.93B
Average
165.66B
Median
Enterprise Value Benchmarks
Amgen Inc | 221.93B |
Gilead Sciences Inc | 104.76B |
Johnson & Johnson | 379.58B |
Eli Lilly and Co | 755.52B |
2seventy bio Inc | 65.36M |
Enterprise Value Related Metrics
Net Income (Quarterly) | -11.91B |
Revenue (Quarterly) | 11.86B |
Total Expenses (Quarterly) | 10.35B |
EPS Diluted (Quarterly) | -5.89 |
Gross Profit Margin (Quarterly) | 75.29% |
Profit Margin (Quarterly) | -100.4% |
Earnings Yield | -7.04% |
Operating Earnings Yield | 8.04% |
Normalized Earnings Yield | 1.754 |